58 results about "Salbutamol Sulphate" patented technology

The invention discloses a production technology for synthetizing salbutamol sulphate, and relates to the field of chemical synthesis. The production technology comprises the following steps: firstly, performing an Friedel-crafts acylation reaction on salicylal to obtain a chemical compound 3, performing a substitution reaction of tert-butylamine, protecting dihydroxy by propylidene under the catalysis of concentrated sulfuric acid through the reduction of potassium borohydride or sodium borohydride, then performing extraction for desalting, and generating a hydrolysis reaction under acid conditions to obtain sulphuric acid salbutamol. The production technology disclosed by the invention is easy to control and operate, raw materials are simple and easy to obtain, the total mol yield is as high as 40%, the product purity is as high as 99.5%, and the product cost is low.

The invention belongs to the technical field of medicines. The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for preventing and treating COVID-19 (diseases caused by novel coronaviruses) and a preparation method thereof. The pharmaceutical composition comprises active ingredients of mycobacterium vaccae for injection and salbutamol sulfate, and the weight ratio of the mycobacterium vaccae for injection to the salbutamol sulfate is 1: (50-200). The medicine prepared from the medicine composition can adopt an aerosol inhalation treatment mode, and through short-term aerosol inhalation, the compliance of a patient can be improved by providing the medicine with a specific purpose for the patient, so that the patient can take the medicine conveniently, and the medical cost is reduced. The pharmaceutical composition for preventing and treating COVID-19 disclosed by the invention has the advantages that the COVID-19 can be effectively prevented and treated; severe or critical symptoms of patients are relieved, nucleic acid negative conversion time is shortened by about 4 days averagely, treatment time is correspondingly shortened, other respiratory virus infections can be prevented and treated nonspecifically, and a new way and scheme are provided for clinical prevention and treatment of COVID-19 and respiratory virus infections.

The invention relates to buccal tablets taking salbutamol sulfate and ambroxol hydrochloride as main active ingredients and a preparation method thereof, and aims to provide a new preparation, namely salbutamol sulfate and ambroxol hydrochloride buccal tablets, for the vast number of patients and medical workers. The preparation has quick response, can improve the bioavailability of medicaments, give full play to the treatment effects of the medicaments and reduce adverse reactions, is convenient for children to swallow and for old people to take with reduced dosage, and is convenient to carry, store and transport. The preparation method is simple and suitable for mass production. In the method, the buccal tablets are prepared by adding some specific types of auxiliary materials in certain proportions into the salbutamol sulfate and ambroxol hydrochloride serving as the active ingredients according to the conventional technique of pharmaceutical engineering.

The invention relates to a method for synchronously detecting five related substances in a compound ipratropium bromide solution for inhalation, and belongs to the technical field of drug quality determination methods. High performance liquid chromatography is adopted for detection, a chromatographic column with alkyl bonded silica gel is adopted as a filler, a phosphate buffer solution containingsodium heptanesulfonate is used as a mobile phase A, an organic phase is used as a mobile phase B, and a detection wavelength is 205-300nm. The detection method provided by the invention can effectively separate ipratropium bromide and salbutamol sulfate from other impurities, and has characteristics of simple operation, a comprehensive result, accuracy, reliability and strong specificity.

This invention relates to aerosol formulations of use for the administration of medicaments by inhalation. More particularly, the invention relates to a pharmaceutical aerosol formulation which comprises particulate salbutamol sulphate having a crystalline form in which the outer layer of the crystals is substantially non-amorphous; and 1,1,1,2-tetrafluoroethane. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.

The invention provides a preparation method of salbutamol sulfate, and relates to the technical field of chemical synthesis. The preparation method of salbutamol sulfate comprises the following steps: (a) carrying out reaction on salicylic acid and a tert-butyl amino acetyl halogenating reagent under the action of a chlorinating agent to generate an intermediate 1; (b) reacting the intermediate 1 under the action of Lewis acid to generate an intermediate 2; (c) reacting the intermediate 2 under the action of an acid reagent to generate an intermediate 3; (d) reacting the intermediate 3 with a reducing agent under the action of a catalyst to generate salbutamol; and (e) reacting salbutamol with sulfuric acid to generate salbutamol sulfate. The raw materials are simple and easy to obtain, the reaction condition is mild, the reaction operation is simple, the reaction process is easier to control, and the safety coefficient is high; used raw materials, solvents and the like are environment-friendly; and the yield and purity of salbutamol sulfate are high, and a process route capable of industrially producing a product with higher quality is provided.

The invention relates to an oral compound pharmaceutic preparation for treating asthma, which contains tranilast shown as the formula (I) and salbutamol sulfate shown as the formula (II) or other pharmaceutically allowed active ingredients. The invention also relates to the application of compounds shown as formulas (I) and (II) or pharmaceutically allowed salts thereof in the preparation of an oral therapeutical agent for treating asthma.

The invention provides a salbutamol sulfate solution for inhalation and a preparation method thereof. The prescription of the salbutamol sulfate solution comprises salbutamol sulfate, ipratropium bromide, an isoosmotic adjusting agent, a pH adjusting agent, sodium hyaluronate, carboxymethyl chitosan oligosaccharide and water for injection. The preparation process comprises the following steps: weighing, preparing a solution, adjusting the pH value, filtering, encapsulating, carrying out quality inspection and the like. According to the prescription and the preparation method, the stability ofthe preparation can be improved, meanwhile, the preparation has a good permeation effect, the salbutamol sulfate tolerance can be improved, and the preparation can better play a role.

The invention discloses a salbutamol sulfate solution for inhalation and a preparation method thereof. A formula of the salbutamol sulfate solution comprises salbutamol sulfate, lactose, an isotonicity regulator, a pH adjusting agent, an antioxidant and the balance of water for injection. In a preparation process, carbon dioxide is introduced as the antioxidant, so that the dissolved oxygen content and the residual oxygen content in the solution are reduced. The added lactose not only is beneficial to the flowability of the medicine component salbutamol sulfate, but also can be used for preventing the salbutamol sulfate from being agglomerated together, so that the salbutamol sulfate can be uniformly dispersed in a solution system. According to the salbutamol sulfate solution for inhalation, the impurity content is low, adverse effects of related substances on human health and drug effects are reduced, the stability is higher, the drug content distribution is uniform, and the treatment effect is facilitated.

The invention relates to an ambroxol and salbutamol enteric coatel tablet, and belongs to the field of pharmaceutic preparations. Due to poloxamer 188, meglumine and mannitol which are appropriately added to the enteric coatel tablet, the stability and bioavailability of ambroxol hydrochloride and salbutamol sulfate in the preparation can be remarkably improved, quality is stable, the effect is remarkable, and respiratory system diseases such as acute and chronic bronchitis and asthma can be effectively treated.

The invention relates to the technical field of a medicine preparation, in particular to a salbutamol sulfate inhalation preparation and a preparation method thereof. Per 1000 ml of the salbutamol sulfate inhalation preparation is prepared from the following ingredients: 0.5 to 2.0 g of salbutamol sulfate, 0.1 to 0.4 g of erythromycin, 0.2 to 0.6 g of L-fucose, 1 to 3 g of a taste-masking agent, 4to 8 g of an osmotic pressure regulator, 1 to 5 g of a pH regulator and the balance of injection water. The salbutamol sulfate inhalation preparation has the advantages that the stability is good under the acid condition; the quality control is accurate; the effect is stable; the mouthfeel is good; and the drug compliance is improved.

The invention relates to an ambroxol salbutamol controlled release tablet and belongs to the field of pharmaceutical preparations. The controlled release tablet is suitably added with poloxamer 188, meglumine and mannitol, significant improvement can be given to the stability and bioavailability of ambroxol hydrochloride and salbutamol sulfate in a preparation, the quality is stable, the effect is significant, and effective treatment may be given to respiratory diseases such as acute and chronic bronchitis and asthma.

The invention relates to dropping pills containing ambroxol hydrochloride and salbutamol sulfate and belongs to the field of medicinal preparations. Poloxamer188, meglumine and mannitol are properly added into the dropping pills so that the stability and bioavailability of ambroxol hydrochloride and salbutamol sulfate in the preparation can be remarkably improved, and the dropping pills have stable quality and a remarkable effect and can effectively treat acute or chronic bronchitis, asthma and other respiratory diseases.

The invention relates to a solution containing ambroxol hydrochloride and salbutamol sulfate and belongs to the field of medicinal preparations. Poloxamer188, meglumine and mannitol are properly added into the solution so that the stability and bioavailability of ambroxol hydrochloride and salbutamol sulfate in the preparation can be remarkably improved, and the solution has stable quality and a remarkable effect and can effectively treat acute or chronic bronchitis, asthma and other respiratory diseases.

The invention relates to the technical field of chemical synthesis, in particular to a preparation method of salbutamol sulfate impurities. The method comprises the following steps: (1) dissolving salbutamol sulfate in methanol, carrying out etherification reaction under acidic conditions, performing dissociating with alkali, and carrying out column purification to obtain a methyl ether intermediate; and (2) dissolving the methyl ether intermediate in an organic solvent, adding concentrated sulfuric acid to react with a cyclization reagent, carrying out dissociating by using alkali, and performing purifying by using a column to obtain a product. The technical scheme adopted by the invention has the beneficial effects that the operation is convenient, the reaction conditions are mild and controllable, the reaction stability is high, and the reaction product is high in yield and purity. In addition, the compound shown in the formula I can provide an impurity reference substance meeting requirements for quality control of salbutamol sulfate.

The invention relates to an ambroxol and salbutamol capsule, and belongs to the field of a pharmaceutical preparation. The capsule, which is added with proper amounts of poloxamer 188, meglumine and mannitol, can significantly improve the stability and the bioavailability of ambroxol hydrochloride and salbutamol sulfate in a preparation; and the capsule is stable in quality and significant in effect, and the capsule is capable of effectively treating such diseases of respiratory system as acute and chronic bronchitis, asthma and the like.

The invention relates to ambroxol salbutamol enteric particles, and belongs to the field of pharmaceutic preparations. A proper amount of poloxamer 188, meglumine and mannitol are added in the enteric particles, stability and bioavailability of ambroxol hydrochloride and salbutamol sulfate in preparations can be improved remarkably, the quality is stable, the effect is remarkable, and respiratory system diseases such as acute and chronic bronchitis and asthma can be treated effectively.